Clinical Trials Logo
  1. Home
  2. Branch Retinal Vein Occlusion
  3. NCT01044329
  4. Details
NCT01044329 Clinical Trial

Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

Branch Retinal Vein Occlusion Clinical Trial

— BRVO  

Official title:
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01044329
Other study ID # 8900
Secondary ID
Status Recruiting
Phase Phase 2
First received January 6, 2010
Last updated January 6, 2010
Start date January 2010
Est. completion date December 2010

Study information
Verified date January 2010
Source hahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ophthalmic research center of Labbafinejad Medical Center
Study type Interventional

Clinical Trial Summary

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Recruitment information / eligibility
Status Recruiting
Enrollment 90
Est. completion date December 2010
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Recent onset (less than 3 months) BRVO

Exclusion Criteria:

- Any previous intervention

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Bevacizumab
Intravitreal, 1.25 mg, 3 times, one month apart.
• Triamcinolone Acetonide
Intravitreal, 2 mg, 2 times, two months apart.

Locations
Country Name City State
Iran, Islamic Republic of Imam Hossein medical center Tehran

Sponsors (2)
Lead Sponsor Collaborator
hahid Beheshti University of Medical Sciences Labbafinejad Medical Center

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Visual acuity 6 months No
Secondary central macular thickness 6 months No
See also
  Status Clinical Trial Phase
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Active, not recruiting NCT04120311 - Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Phase 1
Not yet recruiting NCT04601688 - Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. N/A
Completed NCT01968239 - Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT Phase 2
Completed NCT00612261 - Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion N/A
Not yet recruiting NCT03637283 - Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage N/A
Completed NCT01976338 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) Phase 3
Completed NCT01471691 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Phase 1/Phase 2
Completed NCT01247220 - REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study Phase 2
Terminated NCT00642226 - Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Phase 3
Terminated NCT05127525 - EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN) Phase 3
Completed NCT01599650 - Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Phase 3
Active, not recruiting NCT04120636 - Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Phase 1
Recruiting NCT01975103 - Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Phase 2
Recruiting NCT01348633 - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye N/A
Completed NCT04740905 - A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Phase 3
Recruiting NCT02527733 - Retinal Sensitivity in BRVO After Anti-VEGF Therapy Phase 4
Completed NCT01396057 - Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) Phase 3
Terminated NCT03802630 - Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion Phase 3
Completed NCT02478515 - Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Phase 4